Breaking News
August 20, 2018 - Medicine on the front line to be presented at Medical Innovation 2018
August 20, 2018 - Harbour Biomed and Kelun-Biotech collaborate to develop, commercialize anti-PD-L1 antibody
August 20, 2018 - The man who sold America on vitamin D — and profited in the process
August 20, 2018 - Finding the light in antimicrobials
August 20, 2018 - Unique pain program helps surgical patients wean off opioids safely and effectively
August 20, 2018 - Strawberries could mitigate colonic inflammation
August 20, 2018 - FDA Accepts New Drug Application (NDA) to Review Midazolam Nasal Spray, an Investigational Product for the Acute Treatment of Seizure Clusters
August 20, 2018 - Using Facebook to help young adults quit smoking
August 20, 2018 - ‘Liquid biopsy’ predicts lymphoma therapy success within days | News Center
August 20, 2018 - 5 Questions with Jordan Orange, Chair of Pediatrics
August 20, 2018 - New assay may help improve both sarcoma diagnosis and treatment
August 20, 2018 - New class of insect repellents to fight against mosquito-borne diseases
August 20, 2018 - ACA Coverage Gains Include Workers Without Insurance
August 20, 2018 - 3-D printed biomaterials for bone tissue engineering
August 20, 2018 - Current surveillance system does not quickly pick up most listeriosis cases in the EU, study reveals
August 20, 2018 - Prenatal exposure to acute stress can affect cognitive function in children of low-income households
August 20, 2018 - New study examines scope of state policies targeting drug use by pregnant women
August 20, 2018 - Researchers find long-term structural, functional brain abnormalities in individuals with AUDs
August 20, 2018 - Shortage of insurance fraud cops sparks campaign debate
August 20, 2018 - Researchers find STAT3 as therapeutic target for chronic active EBV infection
August 20, 2018 - Health Tip: Keep Diabetic Feet Healthier
August 20, 2018 - FDA approves brain stimulation device for OCD
August 20, 2018 - NYU Langone’s Perlmutter Cancer Center expands Blood and Marrow Transplant Program
August 20, 2018 - New drug shows potential to prevent painful side effect of therapy
August 20, 2018 - RDMD raises $3 million in seed funding to accelerate rare disease research, drug development
August 20, 2018 - Illicit drug use is higher during celebratory events, may be worse than previously thought
August 20, 2018 - Exploring the relationship between fever and cancer incidence
August 20, 2018 - Study reveals how socioeconomic status affects racial, ethnic disparities in childhood cancer survival
August 20, 2018 - Brain tumors trap immune cells needed to fight cancer in the bone marrow, finds research
August 20, 2018 - Three factors that contribute to physician burnout
August 20, 2018 - Babies dependent on opioids need touch, not tech
August 20, 2018 - Understanding How Antibodies Shape the Gut Microbiome
August 20, 2018 - Cara Therapeutics Doses First Patient in Second Pivotal Phase 3 Efficacy Trial of Korsuva (CR845/difelikefalin) Injection in Hemodialysis Patients with Chronic Kidney Disease-Associated Pruritus
August 20, 2018 - Kidney transplant chains more effective in saving lives
August 20, 2018 - Study unravels cellular and molecular mechanisms behind dermal condensate formation
August 20, 2018 - New integrated gene logic-chips could have great value in medical care
August 20, 2018 - FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
August 20, 2018 - Total, open repairs decline for abdominal aortic aneurysms
August 20, 2018 - Novel system can pinpoint ingestible implants inside the body using wireless signals
August 20, 2018 - Infection rates of high risk oral HPV in England found to be lower than expected
August 20, 2018 - Making robots as valuable and trustworthy assistants for medical therapies
August 20, 2018 - Patients with low-risk blood clots can be better treated at home than at hospital
August 20, 2018 - Passive smoking exposure among kids greatly increases COPD risk late in life
August 20, 2018 - Primary Care Provider Burnout Rate Low in Small Practices
August 20, 2018 - Discovery presents treatment hope for Alzheimer’s and other neurodegenerative diseases
August 20, 2018 - Stroke patients appear to receive better care at teaching hospitals with less chance of readmission
August 20, 2018 - Distinct origin of ADHD identified In children with history of traumatic brain injury
August 20, 2018 - AHA: Wildfire Smoke Threatens Health of Those Near and Far
August 20, 2018 - Here’s a mental health workout that’s as simple as ABC
August 20, 2018 - Newly discovered cytoskeleton utilized by cancer cells for survival
August 19, 2018 - Bifidobacteria supplement colonizes gut of breastfed infants
August 19, 2018 - Why patients with Alzheimer’s markers never develop the condition
August 19, 2018 - ACA’s Medicaid expansion associated with increase in prescriptions for opioid use disorder treatment
August 19, 2018 - Important factor may be missing in models used to predict spread of epidemics from climate change
August 19, 2018 - Indian-Americans have fewer sudden infant deaths, study finds
August 19, 2018 - Experts advise against universal genomic screening of newborns
August 19, 2018 - New trial to investigate whether weight loss before conception can make mom and baby healthier
August 19, 2018 - Sun Pharma Announces FDA Approval of Cequa (cyclosporine) Ophthalmic Solution to Treat Dry Eye Disease
August 19, 2018 - Researchers examining Parkinson’s resilience
August 19, 2018 - HPI, INTEGRIS and USPI enter into agreement to offer patients more choice, flexibility of care
August 19, 2018 - Researchers find mechanism that prepares brain to replicate repeated actions
August 19, 2018 - Those who are emotionally stable when young may remain the most stable as they age
August 19, 2018 - URI professor develops simpler and quicker method for detecting impurity in heparin
August 19, 2018 - Mayo Medical Laboratories and NDSC collaborate to develop new patient blood-management solution
August 19, 2018 - Insight into endocrine cancers and treatment options
August 19, 2018 - HPV Legislation Doesn’t Impact Teen Sexual Behaviors
August 19, 2018 - Exenatide treatment alleviated symptoms of depression in patients
August 19, 2018 - Tufts researchers win grant to study integration of genomic sequencing into neonatal care
August 19, 2018 - Novel finger-prick test can help prevent toxoplasmosis
August 19, 2018 - Cosmetic Procedures Boost Well-Being, Poll Shows
August 19, 2018 - Responsive parenting intervention results in lower BMIs through age three
August 19, 2018 - Anticancer drugs can help plants to battle infection
August 19, 2018 - Sunscreen from bathers releases significant quantities of polluting titanium dioxide into the sea
August 19, 2018 - Case Western Reserve gets three-year grant to enhance food systems in Cleveland neighborhoods
August 19, 2018 - Teenagers can thank their parents’ positive attitude for avoiding obesity
August 19, 2018 - Body mass index positively linked with blood pressure
August 19, 2018 - New tool fills gap in Small Molecules market
August 19, 2018 - Study compares survival outcomes in rural and urban cancer patients enrolled in clinical trials
August 19, 2018 - Researchers develop molecular matrix that delivers healing stem cells to injured elderly muscles
August 19, 2018 - Teva and Regeneron Announce Positive Topline Phase 3 Fasinumab Results in Patients with Chronic Pain from Osteoarthritis of the Knee or Hip
Study: Insufficient Oversight on Modifying FDA-Approved Devices

Study: Insufficient Oversight on Modifying FDA-Approved Devices

image_pdfDownload PDFimage_print

Action Points

  • Manufacturers of dermatologic devices are increasingly gaining approval for device modifications via post-initial approval pathways requiring minimal supporting clinical data, which could influence device effectiveness and safety.
  • Note that these data suggest that greater transparency and higher standards of review may improve inconsistencies in usage of pathways for device approvals, and this will allow better assessment of the safety of device modifications.

Dermatologic device makers often slip substantial product changes through FDA clearance by taking advantage of loose premarket approval (PMA) supplement applications, researchers said.

A search through the FDA online PMA database showed that for the 27 Class III dermatologic devices approved between 1980 and 2016 through the PMA pathway, 562 PMA supplements were green-lighted. On the whole, device makers ramped up their use of these supplemental applications over time: in 1980-1989, supplements were approved at 3.7 per year, whereas the 2006-2015 period saw 36.7 supplements approved per year (an 891.9% increase), according to the study published online in JAMA Dermatology.

“This indicates a higher rate of supplements per device-year in dermatology than other reported specialties, including orthopedics, otolaryngology, and cardiology,” said investigators led by Harib Ezaldein, MD, of University Hospitals Cleveland Medical Center. The 27 dermatologic devices that had approved changes were 14 injectables, 11 photodynamic therapies, one dermal replacement matrix, and one diagnostic imaging instrument.

The worry is that dermatology device changes may not be sufficiently backed by clinical data in many cases, the team suggested, noting that the 30-day supplement track that does not require clinical data (meant only for adjustments to a device’s manufacturing process) accounted for 42.5% of supplemental PMA approvals.

Meanwhile, it appeared that the rigorous panel-track pathway was much less popular, coming in at just 2.8% of PMA supplement approvals. This track requires clinical data and is intended for significant changes such as those in device design or performance, or a new indication for use.

It is therefore problematic that another track, the 180-day process, was used for 41.7% of label indication changes instead of the aforementioned comprehensive panel track requiring clinical data and a formal review process. “As manufacturers make increasing use of supplemental applications, minor device changes may occur without supporting clinical data, which could pose a safety risk to patients,” Ezaldein and colleagues wrote.

Indeed, safety issues came up eventually in many cases, with 14.8% of dermatologic devices undergoing low-risk recalls (Class II or III) and 37.0% voluntarily withdrawn by the manufacturer. For example, both injectable products from Merz were recalled after undergoing 135- and 30-day applications).

“The current regulatory environment does not provide sufficient information necessary for dermatologists to make informed clinical judgment regarding potential device problems,” the researchers emphasized. “There is a dearth of FDA review memos in dermatology, which are normally published to disclose information about modifications. Increasing disclosure about device modifications across all supplementary pathways may promote more reliable safety in Class III dermatologic devices.”

Caveats to the study include the exclusion of devices approved through the cheaper and less robust 510(k) pathway, the authors acknowledged.

Nonetheless, they suggested that to make devices safer for patients, an advisory board tasked with reviewing a product for clinically significant device drift after a defined number of years or PMA supplement applications should be created.

Employees of the FDA responded in an accompanying editorial that the agency is in fact making efforts to improve how it assesses medical device safety: In building the National Evaluation System for Health Technology (NEST), it “will link and synthesize data from different sources across the medical device landscape, including clinical registries, electronic health records, and medical billing claims,” wrote Laura Marquart, MD, and colleagues from the FDA Center for Devices and Radiological Health in Silver Spring, MD.

“The FDA anticipates exponential growth in knowledge about actual clinical use of specific devices through NEST, which will more efficiently generate evidence for, and decrease the time and cost of, medical device evaluation,” the editorial continued. “Concurrently, the FDA is seeking ways to enhance the robustness of available clinical evidence through the development and coordination of registries.”

Both Ezaldein and co-authors and Marquart and co-authors reported having no relevant conflicts of interest.

2018-01-25T13:00:00-0500

Tagged with:

About author

Related Articles